Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Stressgen (TSE:SSB) said in a Phase II trial in 27 pediatric patients with recurrent respiratory papillomatosis (RRP), its HspE7 significantly
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury